Nexus Precision Health, a precision medicine technology company, announced it has acquired Leal Health, an AI-powered patient decision-support platform. Financial terms of the transaction were not disclosed.
The combined company connects more than 250,000 patients, 40,000 clinicians, and over 90 biopharma partners, forming a real-world network designed to operationalize precision medicine and drive measurable outcomes. The integrated platform is built to match patients with cancer, rare genetic diseases, and mental health conditions to the most appropriate therapy, clinical trial, or expanded access pathway at scale.
Leal Health contributes a patented GEN-AI engine that generates personalized treatment plans, alongside an established ecosystem that includes 40,000 clinicians, 90 biopharma partners, and engagements with two of the five largest U.S. health insurers. The platform has facilitated more than 3 million treatment matches in collaboration with biopharma partners.
Despite rapid advances in AI, clinical adoption has been slowed by limited clinician trust, insufficient real-world validation, and unclear reimbursement models. Nexus said the combined Nexus–Leal platform addresses these barriers by embedding transparent biological reasoning into clinical workflows, generating real-world evidence through routine use, and aligning with value-based care frameworks. The system is designed to quickly and cost-effectively gather real-world data, generate treatment plans, educate physicians and patients, and streamline test ordering, with the goal of helping patients access appropriate treatments sooner while reducing waste across healthcare systems.
Nexus focuses on accelerating treatment access for patients with cancer, rare genetic diseases, and mental health conditions by connecting patients, clinicians, payers, and biopharma stakeholders to identify optimal care options in minutes.
Leal Health is an AI-driven decision-support platform with patented technology aimed at delivering accurate treatment-option data to patients and providers.
KEY QUOTES
“This is a category-building moment that makes precision medicine executable at scale. Together, we can turn precision medicine from a promise into a repeatable system.”
Ascher Shmulewitz, Executive Chairman, Nexus Precision Health
“Our goal is simple: AI tech should not be siloed; implement advanced precision medicine technologies in the real world—so every patient who needs them can benefit.”
Asher Nathan, CEO, Nexus Precision Health
“The fundamentals are rare at this stage: an operationally scalable base, a validated network and established unit economics that enable us to capture significant share of a $250 billion market without rebuilding from scratch. This is a combination of mission and margin that investors rarely see this early.”
Everett Kamin, Board Member And Investor, Nexus Precision Health
“I founded Leal Health because I believe every patient deserves an unbiased view of all their options. By joining Nexus, we can expand the mission into rare genetic diseases and mental health—where patients and families spend years searching for answers.”
Tzvia Bader, CEO, Leal Health
